



Unravelling Cancer's Blueprint

Precision oncology advancing first-in-class therapeutics for patients with high-risk cancers.

Investor Factsheet

AIM: **COIL** | OTCQB: **COTXF**

Why Coiled?

- **TACC3 First Mover:** AO-252 targets a validated cancer dependency with no approved therapy, combining oral dosing and brain penetration against aggressive cancers.
- **Early Clinical Validation:** Phase I data showed an 80% clinical benefit rate, providing initial human proof of concept in advanced cancer patients.
- **Differentiated Profile:** AO-252 combines brain penetration, multimodal activity and biomarker-led patient selection in one oral small molecule designed for difficult-to-treat advanced cancers.
- **Near-Term Catalysts:** Phase I/II dose-expansion cohorts are expected to begin in H2 2026, with multiple clinical and strategic milestones extending through 2027.
- **Pipeline Optionality:** A preclinical STAT6 siRNA program expands Coiled into asthma and severe allergic disease, aligning with investor interest in targeted immunology.
- **Compelling Entry Point:** Coiled's AIM listing and U.S. OTCQB presence provide access to an underfollowed oncology company with multiple strategic value-creation paths.

Commercial Opportunity

AO-252 is being developed within commercially validated oncology markets where precision medicines have already created multi-billion-dollar value.

350K+

Estimated Addressable Patients

Biomarker-defined populations across ovarian, prostate, TNBC, endometrial, gastric, and lung cancers in the US and Europe.

>\$20B

Proven Oncology Markets

PARP, CDK4/6 and AR inhibitors demonstrate the commercial success of precision oncology and biomarker-driven treatment.

>\$3B

Recent Strategic Transaction Benchmark


Johnson & Johnson's acquisition of Halda highlights continued pharmaceutical demand for differentiated early-stage precision oncology assets.

Commercial Validation

DNA Repair PARP inhibitors established multi-billion-dollar markets by targeting DNA repair biology.

Precision Medicine CDK4/6 inhibitors demonstrated the value of biomarker-informed treatment selection.

Resistant Disease AR inhibitors created large commercial opportunities by treating patients with therapy-resistant disease.



Value Creation Timeline

2026–2027 CLINICAL MILESTONES

H2 2026: Clinical Dataset Build-Out

- Data set from new gen formulation
- Dose escalation expansion data from new gen formulation
- Enrolment acceleration
- Expansion cohorts initiated
- Target 20–30 patients treated
- Trial initiation

H1 2027

- Key Value Inflection
- Preliminary efficacy dataset
- ~50-patient safety database
- Biomarker validation
- Indication specific cohort updates
- Partnering data package

H2 2027

- Strategic Execution
- Big Pharma partnering discussions
- Registrational pathway alignment
- RP2D confirmation
- Potential Phase 2 strategy

Recent Oncology Transactions

Comparable transactions vary by modality and maturity but demonstrate sustained pharmaceutical demand for differentiated early-stage oncology assets.

DATE	ACQUIRER	TARGET	UPFRONT PAYMENT	MILESTONES / CVRS	TOTAL POTENTIAL VALUE	PATIENT NUMBER	PHASE	INDICATIONS
Jul-26	Novartis	Myricx Bio	\$1 Billion	-	\$400 Million	18	Pre-clinical / ADC payload with differentiated MOA	Multiple solid tumours
Apr-26	Eli Lilly	Kelonia	\$3.25 Billion	\$3.75 Billion	\$7.0 Billion	4	(Platform play)	Leukemia
May-26	Merck	Terns Pharma	-	-	\$5.7 Billion	85	Phase 1/2	Chronic Leukemia
Nov-25	J&J	Halda	\$3.05 Billion	-	\$3.05 Billion	31	Phase 1/2	Prostate and ER Breast
Jan-25	Eli Lilly	Scorpion	\$1.5 Billion	\$1.0 Billion	\$2.5 Billion	40-50	Phase 1	ER+ Breast
Jan-24	J&J	Ambxr	\$2.0 Billion	-	\$2.0 Billion	51	Phase 1	Prostate
May-24	Genmab	Profound Bio	\$2.0 Billion	-	\$2.0 Billion	80	Phase 1/2	Ovarian & Endometrium

Harbor Access Investor Relations

Matt Kelly:

matt@harbor-access.com +1 475 477 9403

AIM: **COIL** | OTCQB: **COTXF**

AIM Admission 27 March 2026

Placing Price 10 pence per share

Gross Fundraise £8.5 million (~\$11.3M USD)

Market Cap ~£40 million (May 2026)
Share price ~10p

Total Shares Outstanding 425,856,539